{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:12:34Z","timestamp":1793351554689,"version":"4.5.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Glioblastoma (GBM) is the most common malignant primary brain tumor in adult patients and has a poor prognosis despite current multimodal approaches that include surgery, radiation therapy, and chemotherapy. Local recurrence is almost inevitable, and treatment options for relapsed disease are limited. Poly-ADP-ribose polymerase inhibitors (PARPi) are standard of care in several advanced\/metastatic solid malignancies including ovarian, breast, and prostate cancer. In GBM, PARPi could represent a novel promising class of therapeutic agents enhancing DNA repair defects present in specific GBM molecular subtypes. Indeed, these agents act by blocking DNA damage repair, amplifying the lethality of DNA-damaging therapies such as temozolomide (TMZ) and radiotherapy. Several PARPi have been investigated in combination with standard GBM therapy, without significant clinical improvement. However, their efficacy is strongly influenced by their ability to cross the blood-brain barrier and the presence of tumor resistance mechanisms. Clinical trials suggest that patient selection using molecular biomarkers and the timing of PARPi administration are crucial for maximizing therapeutic benefit. The choice of PARPi with optimal trapping and blood-brain barrier penetration capacity, together with molecular stratification based on genomic and expression profiles, appears crucial for the effective use of these agents in glioblastoma. This review investigates the biological mechanisms associated with PARPi within GBM tumor cells and assesses which patients could be the best candidates for PARPi treatment based on molecular profiling of the disease.<\/jats:p>","DOI":"10.3389\/fonc.2026.1713069","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:44:38Z","timestamp":1774957478000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review"],"prefix":"10.3389","volume":"16","author":[{"given":"Giovanni","family":"Dima","sequence":"first","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]},{"name":"Unit of Oncology, University Hospital of Pisa","place":["Pisa, Italy"]},{"name":"Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa","place":["Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Nunno","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Aprile","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Gatto","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Tosoni","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Maria","family":"Argento","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Margotti","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bartolini","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Franceschi","sequence":"additional","affiliation":[{"name":"Nervous System Medical Oncology Department, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto delle Scienze Neurologiche di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109663","DOI":"10.1016\/s0167-8140(24)03472-8","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3892\/ijo_00000626","article-title":"Glioma","volume":"10","author":"Weller","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.0023","article-title":"Glioblastoma and other primary brain Malignancies in adults: a review","volume":"329","author":"Schaff","year":"2023","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41467-023-35957-8","article-title":"Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma","volume":"14","author":"Zhou","year":"2023","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.04.004","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1042\/bj20080413","article-title":"Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining","volume":"417","author":"Mahaney","year":"2009","journal-title":"Biochem J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102850","article-title":"PARP inhibitors in gliomas: mechanisms of action, current trends and future perspectives","volume":"131","author":"Cella","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/po.22.00525","article-title":"Mismatch repair deficiency and Lynch syndrome among adult patients with glioma","volume":"7","author":"Benusiglio","year":"2023","journal-title":"JCO Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105397","article-title":"ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification","volume":"299","author":"Rouleau-Turcotte","year":"2023","journal-title":"J Biol Chem"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14194817","article-title":"Nerve density and neuronal biomarkers in cancer","volume":"14","author":"Ali","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dnarep.2025.103873","article-title":"Multiple functions of PARP1 in the repair of DNA double strand breaks","volume":"152","author":"Ortega","year":"2025","journal-title":"DNA Repair (Amst)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-019-0379-2","article-title":"Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Chem Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1158\/2159-8290.cd-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.114.222448","article-title":"Trapping poly(ADP-ribose) polymerase","volume":"353","author":"Shen","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.seminoncol.2023.09.005","article-title":"PARP inhibitors: a review of the pharmacology, pharmacokinetics, and pharmacogenetics","volume":"51","author":"Zeng","year":"2024","journal-title":"Semin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2549","article-title":"EGFR amplification induces increased DNA damage response and renders selective sensitivity to talazoparib (PARP inhibitor) in glioblastoma","volume":"26","author":"Wu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2174\/138161211797440186","article-title":"Breast cancer resistance protein and P-glycoprotein in brain cancer: two gatekeepers team up","volume":"17","author":"Agarwal","year":"2011","journal-title":"Curr Pharm Des"},{"key":"B21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s13346-021-00962-1","article-title":"Correction to: Asymmetric flow field-flow fractionation as a multifunctional technique for the characterization of polymeric nanocarriers","volume":"11","author":"Quattrini","year":"2021","journal-title":"Drug Delivery Transl Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.03.004","article-title":"Induced pluripotent stem cell-derived cardiomyocytes for drug development and toxicity testing","volume":"143","author":"Sinnecker","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdz005","article-title":"Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models","volume":"1","author":"Sambade","year":"2019","journal-title":"Neuro-Oncol Adv"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-17-0365","article-title":"Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma","volume":"16","author":"Kizilbash","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11095-014-1442-z","article-title":"Breast cancer resistance protein (BCRP\/ABCG2) and P-glycoprotein (P-GP\/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699)","volume":"32","author":"Durmus","year":"2015","journal-title":"Pharm Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2275-x","article-title":"Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study","volume":"131","author":"Chabot","year":"2017","journal-title":"J Neuro-Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: from specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.939570","article-title":"Role of PARP inhibitors in glioblastoma and perceiving challenges as well as strategies for successful clinical development","volume":"13","author":"Bisht","year":"2022","journal-title":"Front Pharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.362","article-title":"PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation","volume":"2","author":"van Vuurden","year":"2011","journal-title":"Oncotarget"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-024-01024-7","article-title":"Role of BRCA1 in glioblastoma etiology","volume":"47","author":"Harbi","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-1391","article-title":"BMN 673, a novel and highly potent PARP1\/2 inhibitor for the treatment of human cancers with DNA repair deficiency","volume":"19","author":"Shen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-0084","article-title":"ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy","volume":"20","author":"Lin","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab111","article-title":"A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.4361","article-title":"Efficacy of adding veliparib to temozolomide for patients with MGMT-methylated glioblastoma: a randomized clinical trial","volume":"10","author":"Sarkaria","year":"2024","journal-title":"JAMA Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0110","article-title":"Phase II study of iniparib with concurrent chemoradiation in patients with newly diagnosed glioblastoma","volume":"25","author":"Blakeley","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1200\/jco.2022.40.16_suppl.2035","article-title":"Multicenter phase II trial of the PARP inhibitor olaparib in recurrent IDH1- and IDH2-mutant glioma","volume":"3","author":"Fanucci","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-14-0810","article-title":"MGMT expression predicts PARP-mediated resistance to temozolomide","volume":"14","author":"Erice","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad102","article-title":"Combined inhibition of topoisomerase I and poly(ADP-ribose) polymerase: a synergistic therapeutic strategy for glioblastoma with phosphatase and tensin homolog deficiency","volume":"5","author":"Kim","year":"2023","journal-title":"Neuro-Oncol Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-09-4295","article-title":"PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors","volume":"70","author":"McEllin","year":"2010","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","article-title":"Proteogenomic and metabolomic characterization of human glioblastoma","volume":"39","author":"Wang","year":"2021","journal-title":"Cancer Cell"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713069\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T11:44:38Z","timestamp":1774957478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1713069\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":42,"alternative-id":["10.3389\/fonc.2026.1713069"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1713069","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1713069"}}